@cittumkur.org
Professor and Head
Channabasaveshwar Institute of Technology, Gubbi, Tumkur, Karnataka, India
After having served in various industries (R & Ds) , presently working as Professor and Head , Department of Chemistry in an Engineering College (since 2010), in Karnataka. Have got 24 years of experience in teaching and research. I did complete my doctorate degree in 'Synthetic organic chemistry' , from Karnataka University, Dharwad in 1996 as a regular schoar and CSIR-SRF (New Delhi) from 1993-1998.
M.Sc., Ph.D., PGDIB
Synthetic, heterocyclic, Pharmacological, Drug Intermediates, Speciality Chemicals, Nucleosides and Nucleotides
Some 1,2,4-Triazoles and their derivatives will be prepared and tested for pharmacological properties
Scopus Publications
Scholar Citations
Scholar h-index
Scholar i10-index
Vedavathi Rangaswamy and Umesh Laddi
Bentham Science Publishers Ltd.
Abstract: The present review aims to summarize the antitubercular profile of 1,2,4-triazole, one of the emerging entitled and most sought scaffold with a wide spectrum of biological and pharmacological activities. A systematic review of literature on ‘Heterocycles’, establishes the fact that 1,2,4-triazoles and their derivatives exhibit diverse activities. The 1,2,4-triazole core is found in therapeutically significant drugs and many new ones are in the pipeline. ‘Triazole pharmacophore’ has replaced the widely used ‘imidazole’ as ‘systemically integral azole’ by connecting synchronicity with serendipity. Triazoles are penetratingly studied as ‘diverse therapeutic agents’, due to the improved efficacy and reduced side effects. The extensive anthology of work carried out in the last two decades on 1,2,4-triazole moiety will provide imminent scope for the development of novel potential drugs having better efficacy selectivity and reduced toxicity.
ShobhaR Desai, RajaniS Bennur, S Bennur, U Laddi, and PA Patil
OMICS Publishing Group
In this study, various 5-β-[(N-benzenesulphony/tosyl)-4-(un) substituted anilino]ethyl-2-mercapto-1,3,4-oxadiazole (4a-f), with sulphonamide moiety at the side chain have been synthesised. The structures of the newly synthesised compounds have been established on the basis of their spectral data and elemental analysis. All the compounds were screened for antimicrobial activities against Escherichia coli, Bacillus cirroflagellosus, Aspergillus niger. Colletotrichum capsici and antituberclosis activity against Mycobacterium tuberculosis H37Rv strain. Only two compounds 4b (73%) and 4e (54%), have shown moderate antituberculosis activity. All the compounds have shown moderate antiinflamatory activity and least ulcerogenecity. Most of the compounds have shown significant analgesic activity (64.20-120.72%) in comparison with the standard, Aspirin (49.39%) In the MES method, however only compound 4a, exhibited a protection of 33.33%, and others failed to protect.
S. Desai, U. Laddi, R. S. Bennur and S. Bennur
Various (4-substituted) phenyl-3-β-[(N-benzenesulphonyl/tosyl)-4-(un)substituted anilino]propionylamido-1,3-thiazolidine-4-ones (3a–x) and 1-β-[(N-benzenesulphonyl/tosyl)-4-(un)substituted anilino]-propionylamido-3-chloro-4-(4-substituted)phenyl-azetidin-2-ones (4a–x) have been synthesised by the cyclocondensation of Schiff bases (2a-x) with thioglycolic acid and chloroacetyl chloride, respectively. The structures of the newly synthesised compounds have been established on the basis of their spectral data and elemental analysis. All compounds were evaluated for antimicrobial activities against Escherichia coli, Bacillus cirroflagellosus, Aspergillus niger and Colletotrichum capsici. Most compounds investigated exhibited significant antifungal activity against Colletotrichum capsici, comparable to that of fluconazole, the standard used.
ShobhaR Desai, RajaniS Bennur, S Bennur, U Laddi, and PA Patil
OMICS Publishing Group
In this study, various 3-β-[(N-benzenesulphonyl/tosyl)-4-(un) substituted anilino]ethyl-4-amino-5-mercapto-4(H)-1,2,4-triazoles (5a–f), with biologically active ‘sulphonamide’ moiety as the side chain have been prepared. The structures of the newly synthesised compounds have been established on the basis of their spectral data and elemental analysis. All the compounds were evaluated for antimicrobial activities against Escherichia coli, Bacillus cirroflagellosus, Aspergillus niger and Colletotrichum capsici. Most of the compounds investigated exhibited significant antifungal activity against Colletotrichum capsici, even greater than fluconazole, the standard used. Only two compounds 3f (59%) and 5e (67%), have shown moderate antituberculosis activity. All the triazoles exhibited moderate degree of antiinflammatory activity and least ulcerogenecity. Most of the compounds have shown significant analgesic activity (81.02–120.72%) in comparison with aspirin (49.39%). In the MES method, only compound 3e exhibited a protection of 66.66%, whereas others exhibited minimum protection of (33.33%).
CSIR-SRF and University Minor projects
New heterocycles
Industry and Institute
Various R and Ds for 14 years
Publications in reputed journals, if interesting results are obtained will patent